AATD plasma samples measured for NE- or PR3-specific activity footprints confirm that the levels are increased compared to healthy smoking volunteers and demonstrate different profiles between AAT genotypes that likely reflect the underlying pathophysiological processes (Newby et al., 2019). This evidence concerns the gene PRTN3 and alpha 1-antitrypsin deficiency.